Top ▲


Target id: 2742

Nomenclature: CD3e

Family: CD molecules

Annotation status:  image of a grey circle Awaiting annotation/under development. Please contact us if you can help with annotation.  » Email us

   GtoImmuPdb view: ON :     CD3e has curated data in GtoImmuPdb

Gene and Protein Information
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human - 207 11q23 CD3E CD3e molecule
Mouse - 183 9 A5 Cd3e CD3 antigen, epsilon polypeptide
Rat - 188 8q22 Cd3e CD3e molecule
Previous and Unofficial Names
Cde3 | CD3 antigen, epsilon polypeptide | CD3e molecule, epsilon (CD3-TCR complex) | CD3 molecule, epsilon | CD3 antigen
Database Links
DrugBank Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
RefSeq Nucleotide
RefSeq Protein

Download all structure-activity data for this target as a CSV file

Key to terms and symbols Click column headers to sort
Antibody Sp. Action Affinity Units Reference
blinatumomab Hs Binding 7.0 pKd 9
pKd 7.0 (Kd 1x10-7 M) [9]
Description: Binding of the single-chain Fv portion of blinatumomab to CD3.
muromonab-CD3 Hs Binding - - 10
catumaxomab Hs Binding - - 13
otelixizumab Hs Binding - - 3
Antibody Comments
Visilizumab (HuM291, Nuvion) is a humanized IgG2 anti-CD3e mAb that was engineered to prevent Fc receptor binding [17-18], a concept designed to minimise the mAb-induced cytokine release syndrome associated with exposure to conventional mAbs [6,14]. Visilizumab was developed as a potential immunosuppressive therapeutic for autoimmune diseases and as a prophylactic for transplant rejection. However this mAb failed to show significant clinical efficacy in kidney transplantation, psoriasis, GvHD and IDB, and development appears to have ceased. Visilizumab (humanized m291 IgG2M3 antibody claimed in US5834597) binds human CD3e with a Ka of 50nM [18].
Clinically-Relevant Mutations and Pathophysiology
Disease:  Immunodeficiency 18; IMD18
Synonyms: CD3epsilon deficiency [Disease Ontology: DOID:0060017]
Immunodeficiency 18, SCID variant [OMIM: 615615]
Immunodeficiency 18, Severe combined immunodeficiency variant [OMIM: 615615]
Severe combined immunodeficiency [Orphanet: ORPHA183660]
T-B+ severe combined immunodeficiency due to CD3delta/CD3epsilon/CD3zeta [Orphanet: ORPHA169160]
Disease Ontology: DOID:0060017
OMIM: 615615
Orphanet: ORPHA169160, ORPHA183660


Show »

1. Ahluwalia JP. (2012) Immunotherapy in inflammatory bowel disease. Med. Clin. North Am., 96 (3): 525-44, x. [PMID:22703854]

2. Besançon A, Goncalves T, Valette F, Dahllöf MS, Mandrup-Poulsen T, Chatenoud L, You S. (2018) Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. Diabetologia, 61 (2): 389-398. [PMID:29030662]

3. Bolt S, Routledge E, Lloyd I, Chatenoud L, Pope H, Gorman SD, Clark M, Waldmann H. (1993) The generation of a humanized, non-mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur. J. Immunol., 23 (2): 403-11. [PMID:8436176]

4. Carpenter PA, Appelbaum FR, Corey L, Deeg HJ, Doney K, Gooley T, Krueger J, Martin P, Pavlovic S, Sanders J et al.. (2002) A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood, 99 (8): 2712-9. [PMID:11929757]

5. Carpenter PA, Lowder J, Johnston L, Frangoul H, Khoury H, Parker P, Jerome KR, McCune JS, Storer B, Martin P et al.. (2005) A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol. Blood Marrow Transplant., 11 (6): 465-71. [PMID:15931635]

6. Chau LA, Tso JY, Melrose J, Madrenas J. (2001) HuM291(Nuvion), a humanized Fc receptor-nonbinding antibody against CD3, anergizes peripheral blood T cells as partial agonist of the T cell receptor. Transplantation, 71 (7): 941-50. [PMID:11349730]

7. de Saint Basile G, Geissmann F, Flori E, Uring-Lambert B, Soudais C, Cavazzana-Calvo M, Durandy A, Jabado N, Fischer A, Le Deist F. (2004) Severe combined immunodeficiency caused by deficiency in either the delta or the epsilon subunit of CD3. J. Clin. Invest., 114 (10): 1512-7. [PMID:15546002]

8. Dean Y, Dépis F, Kosco-Vilbois M. (2012) Combination therapies in the context of anti-CD3 antibodies for the treatment of autoimmune diseases. Swiss Med Wkly, 142: w13711. [PMID:23254986]

9. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int. J. Cancer, 100 (6): 690-7. [PMID:12209608]

10. Goldstein G. (1987) Overview of the development of Orthoclone OKT3: monoclonal antibody for therapeutic use in transplantation. Transplant. Proc., 19 (2 Suppl 1): 1-6. [PMID:3105134]

11. Kaufman A, Herold KC. (2009) Anti-CD3 mAbs for treatment of type 1 diabetes. Diabetes Metab. Res. Rev., 25 (4): 302-6. [PMID:19319985]

12. Kawalec P, Mikrut A, Łopuch S. (2014) Systematic review of the effectiveness of biological therapy for active moderate to severe ulcerative colitis. J. Gastroenterol. Hepatol., 29 (6): 1159-70. [PMID:24955447]

13. Linke R, Klein A, Seimetz D. (2010) Catumaxomab: clinical development and future directions. MAbs, 2 (2): 129-36. [PMID:20190561]

14. Norman DJ, Vincenti F, de Mattos AM, Barry JM, Levitt DJ, Wedel NI, Maia M, Light SE. (2000) Phase I trial of HuM291, a humanized anti-CD3 antibody, in patients receiving renal allografts from living donors. Transplantation, 70 (12): 1707-12. [PMID:11152101]

15. Phillips B, Trucco M, Giannoukakis N. (2011) Current state of type 1 diabetes immunotherapy: incremental advances, huge leaps, or more of the same?. Clin. Dev. Immunol., 2011: 432016. [PMID:21785616]

16. Soudais C, de Villartay JP, Le Deist F, Fischer A, Lisowska-Grospierre B. (1993) Independent mutations of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency. Nat. Genet., 3 (1): 77-81. [PMID:8490660]

17. Trajkovic V. (2002) Nuvion. Protein Design Labs. Curr Opin Investig Drugs, 3 (3): 411-4. [PMID:12054088]

18. Tso JY, Cole MS, Anasetti C. (1998) Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same. Patent number: US5834597. Assignee: Protein Design Labs Inc. Priority date: 20/05/1996. Publication date: 10/11/1998.

19. Yu XZ, Bidwell SJ, Martin PJ, Anasetti C. (2001) Anti-CD3 epsilon F(ab')2 prevents graft-versus-host disease by selectively depleting donor T cells activated by recipient alloantigens. J. Immunol., 166 (9): 5835-9. [PMID:11313428]

How to cite this page

CD molecules: CD3e. Last modified on 03/04/2018. Accessed on 19/01/2019. IUPHAR/BPS Guide to PHARMACOLOGY,